case / 25 Jun 2019

Setterwalls has advised RhoVac in connection with a rights issue of approximately SEK 180.9 million

Responsive image

Setterwalls has advised RhoVac AB in connection with a rights issue of shares. Through the rights issue, RhoVac AB will receive gross proceeds of approximately SEK 180.9 million.

RhoVac AB is a biotechnology company conducting research and development of immunotherapeutic drugs. The company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.